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Perturbation of the two-component signal
transduction system, BprRS, results in
attenuated virulence and motility defects
in Burkholderia pseudomallei
Natalie R. Lazar Adler1,6†, Elizabeth M. Allwood1†, Deanna Deveson Lucas1,2, Paul Harrison3, Stephen Watts1,
Alexandra Dimitropoulos2,4, Puthayalai Treerat1,7, Priyangi Alwis1,8, Rodney J. Devenish2,4, Mark Prescott2,4,
Brenda Govan5, Ben Adler1,2, Marina Harper1,2 and John D. Boyce1,2*

Abstract
Background: Burkholderia pseudomallei is the causative agent of melioidosis, a severe invasive disease of humans
and animals. Initial screening of a B. pseudomallei signature-tagged mutagenesis library identified an attenuated
mutant with a transposon insertion in a gene encoding the sensor component of an uncharacterised two-component
signal transduction system (TCSTS), which we designated BprRS.
Results: Single gene inactivation of either the response regulator gene (bprR) or the sensor histidine kinase gene (bprS)
resulted in mutants with reduced swarming motility and reduced virulence in mice. However, a bprRS double mutant
was not attenuated for virulence and displayed wild-type levels of motility. The transcriptomes of the bprS, bprR and
bprRS mutants were compared with the transcriptome of the parent strain K96243. Inactivation of the entire BprRS
TCSTS (bprRS double mutant) resulted in altered expression of only nine genes, including both bprR and bprS, five
phage-related genes and bpss0686, encoding a putative 5, 10-methylene tetrahydromethanopterin reductase involved
in one carbon metabolism. In contrast, the transcriptomes of each of the bprR and bprS single gene mutants revealed
more than 70 differentially expressed genes common to both mutants, including regulatory genes and those required
for flagella assembly and for the biosynthesis of the cytotoxic polyketide, malleilactone.
Conclusions: Inactivation of the entire BprRS TCSTS did not alter virulence or motility and very few genes were
differentially expressed indicating that the definitive BprRS regulon is relatively small. However, loss of a single
component, either the sensor histidine kinase BprS or its cognate response regulator BprR, resulted in significant
transcriptomic and phenotypic differences from the wild-type strain. We hypothesize that the dramatically altered
phenotypes of these single mutants are the result of cross-regulation with one or more other TCSTSs and
concomitant dysregulation of other key regulatory genes.
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Background
Burkholderia pseudomallei is a highly pathogenic Gramnegative organism and the causative agent of melioidosis, a potentially fatal infectious disease of humans and
animals. The bacterium is endemic to tropical regions
including South East Asia and Northern Australia; mortality rates resulting from melioidosis remain extremely
high, with up to 42 % mortality in the Northeastern
region of Thailand and 14 % mortality in Australia’s
Northern Territory [1, 2]. Importantly, a 90 % mortality
rate is associated with septic shock [3]. In Northern
Australia, melioidosis accounts for 32 % of communityacquired bacteraemic pneumonia and 6 % of all bacteraemias [4], while in the Northeastern region of Thailand,
the disease accounts for 20 % of all community-acquired
septicaemias [5] and is the third most common cause of
death from an infectious disease [2]. The complex clinical spectrum of melioidosis, the potentially rapid progression of disease and the fact that B. pseudomallei is
innately resistant to a wide range of antimicrobial agents
[6–8] makes treatment of this disease difficult.
For B. pseudomallei and most other opportunistic
pathogens, the ability to sense external signals is critical
for the transition from their environmental niche into
the eukaryotic host, as well as for survival within specific
niches within the host. Prokaryotic two-component signal transduction systems (TCSTS) constitute a critical
set of regulators which act to sense environmental signals and respond by altering gene expression [9–11].
TCSTS generally consist of a membrane-bound sensor
kinase (SK) and a cytosolic DNA-binding response regulator (RR) [11]. The SK protein senses extracellular stimuli and responds through the autophosphorylation of a
specific histidine residue. This phosphoryl group is then
transferred to an aspartate residue on the cytoplasmic
RR leading to a conformational change that activates the
RR, resulting in the altered expression of a specific set of
genes [12]. TCSTS components are promising drug
targets as these systems are not present in mammalian
cells and inhibitors that target TCSTSs are likely to
function in a manner distinct from existing antimicrobial
agents, thereby providing an alternative treatment for
multidrug resistant bacteria [13]. Moreover, many
TCSTS regulate expression of virulence genes and therefore drugs that target TCSTS could reduce virulence
without affecting bacterial viability and thus reduce the
development of antimicrobial resistance during treatment regimens [14].
The genome of B. pseudomallei strain K96243 encodes
more than 60 TCSTS [15] but only a few have been
characterized including BPSL2024-5, VirAG, MrgRS and
IrlRS. The IrlRS system is involved in the regulation of
B. pseudomallei invasion of epithelial cells as well as
heavy metal resistance. However, an irlR mutant was not
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attenuated for virulence in the C57BL/6 mouse, infant
diabetic rat and Syrian hamster models [16, 17]. The
MrgRS system responds to temperature, with increased
expression of mrgR and mrgS observed during growth at
37 °C compared to 25 °C. This system may be involved
in pathogenesis, but its role in virulence has not been
specifically tested [18]. The VirAG system regulates the
expression of the type VI secretion system cluster 1
(T6SS-1) during growth within macrophages. Both a
virG mutant and a T6SS-1 mutant were attenuated for
virulence [19]. The gene bpsl2025, encoding the SK of a
TCSTS, was first identified in an in vivo hamster infection microarray study and a directed bpsl2025 mutant
was significantly attenuated in the hamster model (≥3log increase in ID50) [20].
Here we characterise a TCSTS in B. pseudomallei that
we have named BprRS. Inactivation of the entire BprRS
system via inactivation of both genes had no effect on
virulence or motility and RNA expression analysis of the
double bprRS mutant revealed few changes in gene
expression. However, inactivation of only one component (either bprR or bprS) led to an attenuated phenotype in both virulence and motility. High-throughput
RNA sequencing (RNA-seq) comparing the transcriptomes of the bprS and bprR mutants with the parent
strain of B. pseudomallei revealed a large number of expression changes in genes required for chemotaxis, flagella biosynthesis and production of malleilactone.
Furthermore, many transcriptional regulators were also
differentially expressed in the single gene mutant strains.
We propose that the altered phenotypes displayed by the
bprR and bprS single mutants are due to the orphaned
sensor or the orphaned response regulator (respectively)
engaging in cross-talk interactions with one or more of
the other B. pseudomallei TCSTS.

Results
Identification of an attenuated B. pseudomallei bprS
(bpss0687) signature-tagged transposon mutant

A signature-tagged library of 336 B. pseudomallei
K96243 mutants was constructed and screened for reduced in vivo growth in the acute (BALB/c) mouse melioidosis model. Mutants displaying reduced hybridisation
in the output pools were tested individually for an in
vivo growth defect by competitive growth assays. Five
mutants were identified that displayed a statistically significant in vivo growth defect (P < 0.001). Four of the attenuated mutants contained transposon insertions
within genes required for the biosynthesis of 1,3-linked
2-O-acetyl-6-deoxy-β-D-manno-heptopyranose capsular
polysaccharide (three in wzm2, one in wcbQ). This locus
has previously been shown to be important for B. pseudomallei virulence [21, 22]. The fifth attenuated mutant
contained a Tn5 insertion within bpss0687 (112 bp from
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the 3′ end) and this mutant was designated bprS::Tn5
(Fig. 1a). The presence of a single transposon insertion
in this mutant was confirmed by Southern blot analysis
(data not shown). The ID50 of the B. pseudomallei parent strain K96243 and the bprS::Tn5 mutant was determined in groups of five BALB/c mice following
inoculation via the intranasal (i.n.) or intraperitoneal
(i.p.) routes of infection. For the i.n. route of infection,
the ID50 of the bprS::Tn5 mutant was >1.3 × 107 CFU
while the parent strain K96243 was <1.2 × 104 CFU. For
the i.p. route of infection, the ID50 of the bprS::Tn5 mutant was >1.6 × 104 CFU compared with <1.2 × 103 CFU
for the parent strain K96243. Therefore, the bprS::Tn5
mutant was attenuated for virulence via both infection
routes in BALB/c mice. Importantly, the bprS::Tn5 mutant displayed normal in vitro growth in both rich
medium (2YT) and minimal medium (M9) indicating
that the attenuated phenotype was not due to a general
growth defect (data not shown).
Bioinformatic analysis of BPSS0687 revealed that the
predicted protein sequence displayed significant amino
acid identity to a number of characterised histidine kinases, including QseC from Pseudomonas spp. (92 %
coverage, 39 % identity). Several conserved amino acid
domains were identified within the predicted SK, including a catalytic histidine kinase-like ATPase, C-terminal
domain (HATPase_c), a histidine kinase A domain
(HisKA), a HAMP (histidine kinases, adenylyl cyclases,
methyl-accepting chemotaxis proteins, and phosphatases) signal transduction domain and two transmembrane regions flanking the predicted stimulus-specific
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region (Fig. 1a). Located immediately upstream of the
histidine kinase gene was a gene encoding a protein with
receiver and effector domains typical of a RR (bpss0688).
RT-PCR using primers that spanned the two genes indicated that bpss0687 and bpss0688 were co-transcribed
(data not shown). Together these data indicate that
bpss0687 and bpss0688 encode a cognate TCSTS pair
named BprRS.

Generation of directed bprS, bprR and bprRS mutants and
associated virulence studies

To confirm that inactivation of bprS led to an attenuated
phenotype, a directed bprS mutant was constructed
using double-crossover insertional mutagenesis (Fig. 1a).
We first compared the growth of the parent strain
K96243 and the mutant in BALB/c mice using competitive growth assays. The bprS mutant displayed normal in
vitro growth (data not shown) but the in vivo competitive index of the bprS mutant was 0.094 ± 0.08, indicative
of an approximately 10-fold reduced growth rate in vivo
compared to the parent strain. The attenuated phenotype was then confirmed using virulence trials in BALB/
c mice (Fig. 2). Mice infected with the parent strain
K96243 displayed signs of illness by 28–50 h (days 2–3)
and eight of the nine mice were euthanized by 190 h
(day 8) after infection. In contrast, the survival rate in
the group infected with the bprS mutant was significantly increased (Fisher’s exact test; P = 0.015), with only
two mice developing late stage signs of infection and required euthanasia after 190 h.

Fig. 1 Schematic representation of the bprR (bpss0688) and bprS (bpss0687) genes in the B. pseudomallei K96243 wild-type strain and each of the bprS
and bprR mutants. Panel a, organisation of the bprRS genes in B. pseudomallei wild-type showing the conserved amino acid domains encoded within
each gene. Domains shown are the receiver and effector domains within bprR and, within bprS, the following domains: transmembrane regions 1 and
2 (TMR1 and 2) between which the stimulus-specific region is located, the HAMP (histidine kinases, adenylyl cyclases, methyl-accepting chemotaxis
proteins, and phosphatases) signal transduction domain, the HisKA (histidine kinase A) dimerization/phosphoacceptor domain and the HATPase_c
(histidine kinase-like ATPase catalytic) domain. The relative position of the insertion in each of the single mutants is shown below the gene schematic.
Panel b, schematic representation of the regions remaining in each gene and the relative position of the tetracycline gene cassette in the bprRS
double mutant
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Fig. 2 Kaplan-Meier survival curves for groups of mice infected
intranasally with the B. pseudomallei wild-type or the bprS, bprR
or bprRS mutant strains. Mice were infected with the following
doses; wild-type strain, 6 × 104 CFU; bprS mutant, 8 × 104 CFU,
bprR mutant, 3 × 104 CFU, bprRS mutant 9 × 104 CFU

To further characterise the BprRS TCSTS, a directed
bprR mutant (Fig. 1a) and a bprRS double mutant
(Fig. 1b) were also constructed by double-crossover insertional mutagenesis. The bprR mutant was also highly
attenuated for virulence (P = 0.003) with only a single
mouse showing late-stage disease signs at 150 h (day 6)
(Fig. 2). In contrast, the bprRS mutant was not attenuated for virulence as determined by numbers of surviving mice (Fisher’s exact test; P = 0.13) or time to
euthanasia (Log-rank Mantel-Cox test; P = 0.062) (Fig. 2).
These data clearly show that separate inactivation of
BprRS TCSTS SK or the RR resulted in decreased virulence, but inactivation of both genes in the BprRS
TCSTS system did not.
Transcriptomic analyses of the bprRS double mutant

TCSTS are critical regulators of bacterial gene expression. To understand why the bprRS mutant was not attenuated for virulence, while the single bprR and bprS
mutants were, we analysed the transcriptomes of all
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three mutant strains and the wild-type strain. Firstly, to
identify the genes controlled by the BprRS system we
compared the transcriptomes of the bprRS double mutant and the parent strain, K96243. In total, only nine
genes were differentially expressed (five with increased
and four with decreased expression) in the bprRS double
mutant (Table 1). Both the truncated bprR and bprS
gene fragments showed increased expression, suggesting
that the BprRS TCSTS likely regulates its own expression. Two genes, bpss0686 and bpss0686a, located immediately upstream of the bprRS TCSTS genes but
transcribed from the other strand, showed increased expression in the bprRS double mutant (Table 1); these
genes were also identified as differentially expressed in
the bprS single mutant (Table 2). Bioinformatic analyses
of bpss0686a revealed no additional information on the
open reading frame and analysis of the RNA-seq data revealed that only a single sequence read of the 13 million
sequence reads generated from the parent strain
(K96243) matched this region, indicating that bpss0686a
may not encode a functional protein, or it is not
expressed under the conditions used for bacterial
growth. Bioinformatic analysis of bpss0686 revealed that
it encoded a putative enzyme belonging to the flavinutilizing monoxygenase super family and the nitrilotriacetate monoxgenase sub-family. Moreover, the encoded
protein had 65 % identity (96 % coverage) to the 5, 10methylene tetrahydromethanopterin reductase in Methylobacterium extorquens that is required for one carbon
metabolism [23]. Five phage-associated genes were also
differentially expressed in the bprRS double mutant; four
of these showed decreased expression and one, encoding
a phage membrane protein (bpss1087), showed increased
expression. Three of the phage genes, bpss1087 and
bpss1066 (encoding a predicted phage terminase/endonuclease subunits), and bpss1072 (encoding a protein of

Table 1 Genes with differential expression in the bprRS double mutant compared to expression in the wild-type parent strain
Locus tag

Gene product/description

bprRS mutant Expression (log2)

FDR

3.36

3.21E-07

Increased expression in bprRS double mutant relative to wild-type expression
BPSS0686

putative 5, 10-methylenetetrahydro-methanopterin reductase

BPSS0686a

protein of unknown function

5.63

7.35E-05

BPSS0687

BprS-sensor kinase protein

4.34

1.67E-07

BPSS0688

BprR-response regulator protein

2.07

1.31E-05

BPSS1087

phage membrane protein

1.13

3.41E-03

protein of unknown function with ATPase domain, putative phage-encoded

−5.17

1.17E-04

BPSL0146

membrane protein

−3.48

9.28E-06

BPSS1066

phage terminase, endonuclease subunit

−3.62

2.86E-03

BPSS1072

phage-acquired protein

−4.89

9.28E-06

Decreased expression in bprRS double mutant relative to wild-type expression
BPSL0145

Genes were identified as differentially expressed if they showed >2-fold expression change (log2 > 1.0 or log2 < −1.0) compared to the wild-type strain with a False
Discovery Rate (FDR) of <0.01
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Table 2 Genes with increased expression in either the bprR and/or bprS single mutants
Locus tag

Gene
name

Description

bprS mutant
Expression (log2)

BPSL0026

fliL

flagellar basal body-associated protein FliL

2.09

BPSL0028

fliN

flagellar motor switch protein

2.25

BPSL0031

fliQ

flagellar biosynthesis protein

2.15

bprS
bprR mutant
mutant FDR Expression (log2)
8.28E-03

bprR
mutant FDR

1.82#

1.52E-02

5.34E-03

1.94

9.47E-03

5.34E-03

1.93#

1.08E-02

BPSL0067

protein of unknown function

2.54

2.16E-05

2.30

2.20E-05

BPSL0068

putative lipoprotein

2.46

2.16E-05

2.30

2.11E-05

BPSL0069

putative anti-sigma factor

1.02

4.78E-03

0.89

1.09E-02

BPSL0071

putative catalase

1.31

4.26E-03

1.47

2.44E-03

BPSL0225

putative flagellar hook-length control protein

1.76

1.24E-03

1.24

6.62E-03

flagellar fliJ protein

1.87

1.75E-03

1.34#

1.09E-02

fliI

flagellum-specific ATP synthase

1.94

5.34E-03

1.54#

1.32E-02

fliH

flagellar assembly protein H

2.04

8.43E-03

1.69#

1.69E-02

fliF

flagellar MS-ring protein

2.14

8.20E-03

1.75#

1.64E-02

fliE

flagellar hook-basal body complex protein

1.81

8.84E-03

1.39#

2.52E-02

BPSL0269

flgA

flagellar basal body P-ring biosynthesis protein FlgA 2.09

2.38E-03

1.58#

1.08E-02

BPSL0271

flgC

flagellar basal body rod protein FlgC

6.66E-03

1.75#

1.52E-02

BPSL0226

fliJ

BPSL0227
BPSL0228
BPSL0230
BPSL0231

2.20

BPSL0272

flgD

flagellar basal body rod modification protein

2.12

7.33E-03

1.76#

1.43E-02

BPSL0273

flgE

flagellar hook protein FlgE

1.88

3.02E-03

1.39#

1.22E-02

BPSL0274

flgF

flagellar basal body rod protein FlgF

1.79

4.69E-03

1.29#

1.66E-02

BPSL0275

flgG

flagellar basal body rod protein FlgG

1.92

5.66E-03

1.43#

1.64E-02

BPSL0276

flgH

flagellar basal body L-ring protein

1.88

2.96E-03

1.44#

1.03E-02

BPSL0278

flgJ

flagellar rod assembly protein/muramidase FlgJ

1.83

4.51E-03

1.27#

1.87E-02

mce related protein

1.19

1.26E-03

1.22

7.78E-04

BPSL0812

bpeR

TetR family regulatory protein

1.09

7.33E-03

1.08

8.20E-03

BPSL0814

bpeA

RND family acriflavine resistance protein A
precursor

1.65

2.23E-03

1.56

2.22E-03

BPSL0815

bpeB

RND family acriflavine resistance protein

1.84

7.63E-03

1.79

7.22E-03

BPSL1053

putative lipoprotein

0.48

3.05E-01

1.50

5.74E-03

BPSL1112

putative lipoprotein

1.54

1.55E-03

1.24

6.71E-03

BPSL0403

BPSL1184

putative sugar-related transport, membrane protein

1.01

6.70E-03

0.88

1.37E-02

BPSL1185

protein of unknown function

3.95

3.83E-05

4.04

2.11E-05

BPSL1202

putative transport-related membrane protein

0.61

8.41E-02

1.93

2.32E-04

BPSL1203

putative carbonic anhydrase

0.63

6.17E-02

2.03

9.28E-05

BPSL1254
BPSL1289

osmB

protein of unknown function

1.59

4.26E-03

1.75

2.10E-03

osmotically inducible lipoprotein B precursor

0.72

3.89E-02

1.66

2.80E-04

BPSL1387

protein of unknown function

1.09

1.34E-03

0.77

8.20E-03

BPSL1563

putative membrane protein of unknown
function

1.22

5.17E-04

1.68

4.16E-05

BPSL1564

putative transcriptional regulatory protein

0.50

1.17E-01

1.37

9.39E-04

BPSL1598

putative transport-related, membrane protein

0.28

3.17E-01

1.59

1.66E-04

BPSL1829

putative methyl-accepting chemotaxis protein

1.98

4.26E-03

1.34#

1.89E-02

BPSL1872

putative N-acetylmuramoyl-L-alanine amidase

1.07#

3.99E-02

1.47

9.64E-03

BPSL1931

protein of unknown function

0.83

2.35E-02

1.01

9.10E-03

BPSL2011

putative osmosis-related lipoprotein

−0.35

2.54E-01

1.08

2.78E-03

BPSL2016

protein of unknown function

0.78

5.21E-02

1.30

5.35E-03
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Table 2 Genes with increased expression in either the bprR and/or bprS single mutants (Continued)
BPSL2017

di-haem cytochrome c peroxidase

0.67

1.09E-01

1.38

5.35E-03

BPSL2193

protein of unknown function

0.90

7.52E-03

1.12

2.10E-03

BPSL2282

protein of unknown function

0.62

6.86E-02

1.97

1.20E-04

BPSL2396

protein of unknown function

1.27

7.30E-03

1.30

5.74E-03

BPSL2397

protein of unknown function

1.46

2.48E-03

1.25

5.30E-03

BPSL2398

protein of unknown function

1.12#

1.09E-02

1.18

7.39E-03

BPSL2399

putative glycosyltransferase

1.36

1.55E-03

1.19

2.72E-03

BPSL2409

ABC transporter ATP binding protein

0.85

2.82E-02

1.09

8.00E-03

BPSL2466

protein of unknown function

0.76

1.43E-02

2.03

2.30E-05

BPSL2482

peptidase

1.25

2.38E-03

1.32

1.27E-03

BPSL2483

ribosome-associated GTPase

0.97

5.86E-03

1.01

4.35E-03

BPSL3254B

protein of unknown function

1.63

1.22E-03

1.94

2.75E-04

BPSL3291

fliA

flagellar biosynthesis sigma factor

1.86

2.45E-03

1.50

6.41E-03

BPSL3292

flhG

flagellar biosynthesis protein FlhG

2.21

3.79E-03

1.74#

1.08E-02

BPSL3293

flhF

flagellar biosynthesis regulator FlhF

2.23

1.83E-03

1.75

5.35E-03

BPSL3294

flhA

flagellar biosynthesis protein FlhA

2.09

7.89E-03

1.67#

1.66E-02

putative transferase

1.55

8.43E-03

1.13#

2.51E-02

BPSL3323
BPSL3324

putative keto/oxo acyl-ACP synthase

1.51

7.17E-03

0.98

3.22E-02

BPSL3326

putative keto/oxo acyl-ACP synthase

1.78

8.43E-03

1.39#

1.99E-02

BPSL3327

putative short chain dehydrogenase

1.74

3.62E-03

1.26#

1.52E-02

BPSL3329

Rieske (2Fe-2S) domain-containing protein

1.31

7.21E-03

0.95

2.29E-02

BPSS0215

tar

BPSS0216
BPSS0223
BPSS0236

ltaE

methyl-accepting chemotaxis protein

1.70

6.71E-03

1.35#

1.58E-02

putative membrane protein of unknown function

1.12

4.45E-03

0.82

1.97E-02

protein of unknown function

0.82

8.44E-03

1.44

2.34E-04

L-allo-threonine aldolase

0.96

2.09E-02

1.20

6.20E-03

BPSS0264

protein of unknown function

1.02#

2.56E-02

1.36

6.20E-03

BPSS0298

transport related membrane protein

1.60

1.36E-03

1.07#

1.37E-02

BPSS0299

malM

fatty-acid CoA ligase

2.20

8.23E-03

1.63#

2.27E-02

BPSS0300

malL

malonyl CoA-acyl carrier protein

2.29

2.38E-03

1.60#

1.17E-02

BPSS0301

malK

protein of unknown function

2.24

1.91E-03

1.60

9.10E-03

BPSS0302

malJ

fatty acid biosynthesis-related CoA ligase

2.30

2.96E-03

1.66#

1.29E-02

BPSS0303

malI

diaminopimelate decarboxylase

2.39

8.17E-04

1.81

2.78E-03

BPSS0304

malH

protein of unknown function

2.60

3.60E-04

1.93

1.38E-03

BPSS0305

malG

ketol-acid reductoisomerase

2.51

3.20E-04

1.95

9.39E-04

BPSS0306

malF

multifunctional polyketide-peptide syntase

2.67

5.32E-04

2.14

1.38E-03

BPSS0307

malE

gamma-aminobutyraldehyde dehydrogenase

2.81

1.53E-04

2.35

2.60E-04

BPSS0308

malD

protein of unknown function

2.75

1.55E-04

2.23

3.46E-04

BPSS0309

malC

peptide synthase regulatory protein

2.89

8.78E-05

2.33

2.10E-04

BPSS0310

malB

protein of unknown function

2.98

1.53E-04

2.62

2.20E-04

BPSS0311

malA

multifunctional polyketide-peptide syntase

3.10

5.17E-04

2.87

4.96E-04

BPSS0312

malR

LuxR family transcriptional regulator

1.47

6.27E-04

1.12

2.72E-03

BPSS0317

monooxygenase

1.54

1.55E-03

2.38

6.99E-05

BPSS0325

putative membrane protein of unknown function

0.32

2.91E-01

1.07

3.74E-03

BPSS0337

protein of unknown function

1.38

1.24E-03

1.91

1.20E-04

BPSS0623

outer membrane efflux protein

2.09

5.17E-04

2.27

2.10E-04
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Table 2 Genes with increased expression in either the bprR and/or bprS single mutants (Continued)
BPSS0624

macB

macrolide-specific ABC-type efflux carrier

1.95

1.61E-03

2.22

4.96E-04

BPSS0625

drug-efflux protein

1.97

6.27E-04

2.15

2.33E-04

BPSS0685

protein of unknown function

1.21

6.63E-04

0.89

5.35E-03

BPSS0686

Predicted 5,10-methylene tetrahydromethanopterin
reductase

3.39

1.14E-07

0.35

1.71E-01

BPSS0686aa

protein of unknown function

5.16

8.78E-05

−0.47

5.88E-01

BPSS0687a

sensor kinase protein

5.89

7.90E-09

1.46

2.89E-04

BPSS0688a

response regulator protein

4.56

9.34E-09

4.70

7.98E-09

BPSS0689

protein of unknown function

7.12

7.90E-09

7.78

5.57E-09

BPSS0690

protein of unknown function

6.45

1.06E-08

6.49

9.89E-09

BPSS0692

fumarylacetoacetate (FAA) hydrolase family
protein

2.26

1.55E-04

2.16

2.10E-04

BPSS0693

fumarylacetoacetate (FAA) hydrolase family
protein

2.07

1.53E-04

1.88

2.10E-04

a

BPSS0694

hpcC

5-carboxymethyl-2-hydroxymuconate
semialdehyde dehydrogenase

2.14

2.48E-05

2.18

1.82E-05

BPSS0695

hpcB

3,4-dihydroxyphenylacetate 2,3-dioxygenase

1.81

8.07E-05

1.84

4.84E-05

BPSS0696

hpcD

5-carboxymethyl-2-hydroxymuconate deltaisomerase

2.19

1.53E-04

1.98

2.44E-04

BPSS0697

hpcG

2-oxo-hepta-3-ene-1,7-dioic acid hydratase

1.85

2.01E-04

1.89

1.69E-04

BPSS0698

hpcH

2,4-dihydroxyhept-2-ene-1,7-dioic acid aldolase

2.01

1.55E-04

1.99

1.67E-04

BPSS0724

protein of unknown function

0.83

7.33E-03

1.09

1.38E-03

BPSS0755

LysR family regulatory protein

0.57

3.11E-02

1.03

1.23E-03

BPSS0796A

H-NS-like protein

1.71

2.38E-03

4.39

1.27E-06

BPSS0797

IclR family regulatory protein

1.03

6.40E-02

3.95

1.96E-05

BPSS0798

protein of unknown function

0.68

1.60E-01

3.35

2.11E-05

BPSS0799

diguanylate phosphodiesterase

1.04

9.65E-03

4.48

1.31E-07

BPSS0828

protein of unknown function

0.82

3.54E-02

1.21

5.35E-03

BPSS0852

inosine-uridine preferring nucleoside hydrolase

1.60

6.57E-03

1.74

3.49E-03

BPSS0941
BPSS0946

penA

protein of unknown function

1.07

8.73E-03

1.33

2.78E-03

beta-lactamase precursor

1.94

2.38E-03

2.65

2.44E-04

BPSS1038

protein of unknown function

0.04

9.47E-01

1.66

5.01E-03

BPSS1239

peptidase

0.33

6.92E-01

2.76

2.53E-03

BPSS1250

acetylpolyamine aminohydrolase

0.95

2.14E-02

1.10

9.81E-03

BPSS1275

RNA polymerase sigma factor

1.25

7.92E-03

1.51

2.99E-03

BPSS1296

O-methyltransferase-like protein

0.88

1.11E-02

1.05

4.84E-03

BPSS1553

bprP

Transcriptional regulator

1.57

2.04E-03

1.19

8.84E-03

BPSS1554

bprQ

Protein associated with bprP

1.43

1.28E-03

1.31

2.27E-03

BPSS1862

ABC transport system, ATP-binding protein

1.70

8.43E-03

1.71

7.39E-03

BPSS1866

lipoprotein

0.21

5.80E-01

1.44

2.10E-03

BPSS1867

protein of unknown function

1.42#

1.21E-02

2.20

9.10E-04

BPSS1980

protein of unknown function

0.66

1.61E-02

1.31

2.44E-04

BPSS1996

protein of unknown function

1.13

8.44E-02

2.84

8.95E-04
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Table 2 Genes with increased expression in either the bprR and/or bprS single mutants (Continued)
BPSS2162

protein of unknown function

0.42

5.50E-01

2.13

6.14E-03

BPSS2307

amidase

BPSS2308

protein of unknown function

0.61

1.05E-01

1.47

1.92E-03

1.01

1.26E-03

1.97

1.14E-05

Genes were identified as differentially expressed if they showed >2-fold expression change (log2 > 1.0) compared to the wild-type strain with a False Discovery
Rate (FDR) of <0.01. All significant gene expression changes are shown in bold and the locus tag, gene name and description are shown in bold when significant
expression changes were observed for both mutants
a
Increased RNA expression also observed in the bprRS double mutant (Table 1)
#
Genes showing increased expression of >2-fold with a FDR of >0.01 and <0.05

unknown function), are located on chromosome 2 within
a predicted prophage. The remaining two genes differentially expressed in the bprRS double mutant encoded a
predicted ATPase (bpsl0145) and a phage membrane protein (bpsl0146) that were within a large region on chromosome 1 also containing a predicted prophage.
Transcriptomic analyses of the bprS, bprR single gene
mutants

In order to identify gene expression changes that
resulted from perturbation of the BprRS system via inactivation of bprS, encoding the SK, or bprR, encoding
the RR, we compared the transcriptomes of the bprS
and bprR mutants with the wild-type strain. A total of
170 genes were differentially expressed in one or both of
the single mutants and 57 genes showed increased expression and 16 reduced expression (≥2-fold change in
expression at FDR <0.01) in both the bprS mutant and
the bprR mutants (Fig. 3, Tables 2 and 3); thus, these
gene lists show a high degree of similarity (Fisher’s exact

Fig. 3 A Venn diagram showing the number of B. pseudomallei
genes with increased expression (up arrow) or with reduced expression
(down arrow) in each of the bprR, bprS and bprRS double mutants.
Genes were identified as differentially expressed if they showed >2-fold
expression change (log2 > 1.0) compared to the wild-type strain with a
False Discovery Rate (FDR) of <0.01. The total number of genes in each
mutant showing increased expression (>2-fold) with a more relaxed
FDR of <0.05 are shown in brackets

test; P < 0.001). Moreover, when a slightly less stringent
FDR of <0.05 was applied to the initial gene list generated, 103 of the 171 genes identified were differentially
expressed in both the bprS mutant and the bprR mutant
(87 increased and 16 decreased) (Fig. 3, Tables 2 and 3).
Genes identified with increased expression in the bprS
and bprR single mutants included many involved in the
production of secondary metabolites; bpsl3323-3329 and
bpss0689-0690 involved in fatty acid biosynthesis,
bpss0692-0698 involved in the degradation of aromatic
compounds, and all the genes within the malleilactone
biosynthesis locus (bpss0298-bpss0312).
Two genes encoding methyl-accepting chemotaxis
proteins (MCPs) (bpsl1829 and tar) and at least 19 genes
required for flagella biosynthesis (including fliA encoding the flagella biosynthesis sigma factor) showed increased expression in the bprS single mutant; the
majority of these also showed increased expression in
the bprR mutant although mostly with FDR values between 0.01 and 0.05 (Tables 2 and 4). Genes involved in
antibiotic resistance were also increased in expression
and included bpeR (encoding a TetR family regulator),
bpeA and bpeB that together encode the resistancenodulation-division (RND) multidrug efflux pump
BpeAB-OprA [24]. Other genes involved in antibiotic resistance that were over-expressed included the gene
bpsl2708, encoding a putative metallo-β-lactamase, and
penA that encodes a class A β-lactamase conferring
resistance to ceftazidime [25, 26]. Three genes (bpss0623,
macB and bpss0625) encoding an ABC transporter/type
I secretion system predicted to be involved in drug resistance [27] were also over-expressed in the mutants.
Genes with decreased expression in both the bprR and
bprS mutant included five genes (bpss0515-bpss0520)
located within the type 6 secretion system cluster 2
(T6SS-2). This cluster encodes one of six T6SSs produced by B. pseudomallei (designated T6SS-1through to
T6SS-6) but only T6SS-1 has been determined to have a
role in virulence [28].
Importantly, a large number of regulatory genes were
identified as differentially expressed when the BprRS system
was perturbed by single gene inactivation. Regulatory genes
with increased expression in both the bprS and bprR single
mutants included fliA and bpeR (discussed above) and
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Table 3 Genes with decreased expression in the bprR and/or bprS single mutants
Locus tag

Gene
name

BPSL0153

Gene product/description
putative phage protein

bprS mutant
Expression (log2)
−1.37

bprS mutant
FDR
8.23E-03

bprR mutant
Expression (log2)
−0.27

bprR mutant
FDR
4.60E-01

BPSL0154

phage baseplate assembly protein

−2.44

8.06E-03

−0.60

3.10E-01

BPSL0155

phage baseplate assembly protein

−1.65

2.96E-03

−0.87

4.55E-02

BPSL0156

phage baseplate assembly protein

−1.90

6.75E-04

−0.77

4.26E-02

BPSL0157

phage-encoded modification methylase

−2.80

8.98E-04

−1.14

3.72E-02

BPSL0159

phage tail completion protein

−0.90

1.70E-02

−1.72

1.33E-03

BPSL0169

phage terminase, endonuclease subunit

−2.26

1.02E-03

−0.94

4.27E-02

BPSL0170

phage major capsid protein precursor

−2.19

6.09E-03

−0.94

1.08E-01

BPSL0171

putative phage capsid scaffolding protein

−2.48

8.20E-03

−0.93

1.59E-01

BPSL0347

putative insertion element protein

−2.80

5.12E-03

−3.04

5.01E-03

BPSL0585

protein of unknown function

−1.69

2.38E-03

−2.18

1.04E-03

BPSL0742

protein of unknown function

−0.67

7.95E-02

−1.25

6.20E-03

BPSL0759

protein of unknown function

−1.25

9.45E-03

−0.96

2.92E-02

BPSL0761

protein of unknown function

−1.19

6.70E-03

−0.85

2.91E-02

BPSL1801

putative type-1 fimbrial protein

−1.23

4.28E-03

−1.89

2.60E-04

BPSL2112

hydroxydechloroatrazine ethylaminohydrolase

−1.47

4.03E-02

−2.16

7.22E-03

BPSL2113

putative purine catabolism-related protein

−1.41

7.63E-03

−2.33

7.13E-04

BPSL2114

protein of unknown function

−1.48

5.36E-03

−2.26

3.27E-04

BPSL2115

ureidoglycolate hydrolase

−1.13

1.61E-02

−1.69

2.22E-03

BPSL2116

allantoicase

−1.30

8.28E-03

−1.84

9.39E-04

BPSL2117

putative uricase

−1.04

3.97E-02

−1.73

3.81E-03

BPSL2118

protein of unknown function

−1.18

9.24E-03

−1.83

6.37E-04

BPSL2508

protein of unknown function

−1.48

6.03E-03

−1.07

2.36E-02

BPSL2708

putative exported metallo-beta-lactamase-family
protein

−1.08

6.27E-04

−0.59

1.62E-02

BPSL2972

IclR family regulatory protein

−1.02

2.38E-03

−0.82

8.20E-03

BPSL3171
BPSS0063

dctD

BPSS0070

protein of unknown function

−1.25

6.57E-03

−0.92

2.71E-02

C4-dicarboxylate transport transcriptional
response regulator

−1.21

3.44E-03

−0.95

1.32E-02

IS30 transposase

−0.66

4.42E-02

−1.06

6.19E-03

BPSS0169

protein of unknown function

−1.72

7.67E-03

−1.44

1.90E-02

BPSS0515

type VI secretion-associated protein, ImpA
family

−1.86

2.63E-03

−1.75

5.74E-03

BPSS0516

type VI secretion protein

−1.79

8.28E-03

−1.98

9.46E-03

BPSS0517 EvpB

protein of unknown function

−2.03

1.85E-04

−1.76

5.84E-04

BPSS0518

type VI secretion protein

−1.98

5.17E-04

−1.74

1.41E-03

BPSS0520

type VI secretion protein

−1.36

9.44E-04

−1.27

2.01E-03

BPSS1034

protein of unknown function

−1.12

7.89E-03

−1.69

8.11E-04

BPSS1035

protein of unknown function

−1.74

5.66E-03

−2.24

2.78E-03

BPSS1080

bacteriophage baseplate assembly protein J

−1.47

8.24E-03

−0.54

1.90E-01

BPSS1085

bacteriophage major tail tube protein

−1.47

7.30E-03

−0.75

8.02E-02

BPSS1588

protein of unknown function

−1.57

3.16E-02

−2.21

5.01E-03
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Table 3 Genes with decreased expression in the bprR and/or bprS single mutants (Continued)
BPSS1740

lipB

−0.83

lipase chaperone

3.87E-02

−1.41

5.01E-03

BPSS2136

Family S43 non-peptidase protein

−1.24

2.38E-03

−1.16

3.97E-03

BPSS2138 oppD

oligopeptide transport ATP-binding ABC
transport protein

−1.11

9.63E-03

−1.20

9.13E-03

BPSS2296

transport protein

−2.21

3.62E-03

−1.87

1.14E-02

Genes were identified as differentially expressed if they showed >2-fold expression change (log2 < −1.0) compared to the wild-type strain with a False Discovery
Rate (FDR) of <0.01. All significant gene expression changes are shown in bold and the locus tag, gene name and description are shown in bold when significant
expression changes were observed for both mutants

malR (bpss0312), encoding a regulator that shares identity
(97 %) with MalR in Burkholderia thailandensis, an orphan
LuxR homolog that activates the malleilactone biosynthesis
genes independently of acyl-homoserine lactone and
quorum sensing systems [29, 30]. The genes bprP
(bpss1553), encoding a transmembrane regulator, and
the adjacent gene bprQ, encoding a transmembrane
protein, involved in the control of the BsaN virulence
regulon were also over-expressed. Importantly, the
BsaN virulence regulon includes genes encoding the
type III secretion system locus 3 (TTSS3) [31, 32]. The
expression of bpss0799 in both the bprR and bprS single mutants was also increased (Table 4); the encoded

protein contains an EAL domain and shares significant
identity with cyclic diguanylate phosphodiesterases,
which are known to control motility and biofilm formation in a number of bacteria [33]. Other regulatory
genes with increased expression but in only the bprR
mutant were bpss0797 encoding an IclR family protein, bpss0755 encoding a LysR family protein, and
bpsl1564 that encodes a putative transcriptional regulatory protein (Table 4). Only one regulatory gene
(bpss00070, encoding an IS30 transposase) had decreased expression in the bprR mutant. Regulatory
genes that were reduced in expression but only in the
bprS single mutant included bpsl2972, encoding an

Table 4 Regulatory genes differentially expressed in the bprR and/or bprS single mutants
Locus tag/gene

Description/predicted function

Expression in Expression in
bprS mutant bprR mutant

Two component signal transduction systems
BPSL1829

methyl-accepting chemotaxis
protein

BPSS0063 dctD

Class/Function
Increased

Increased#

MCP/Chemotaxis

C4-dicarboxylate transport protein Decreased

NS

RR/Receiver

BPSS0215 tar

methyl-accepting
chemotaxis protein

Increased

Increased#

MCP/Chemotaxis

BPSS0687 bprS

sensor kinase protein

Increased

Increased

HK/Transmitter

BPSS0688 bprR

response regulator protein

Increased

Increased

RR/Receiver

One component regulators

Domain-input

Domain-output

BPSL0812 bpeR TetR family regulatory protein

Increased

Increased

Not known

TetR_N-DNA binding

BPSL1564

NS

Increased

Not known

HTH_26-DNA binding

transcriptional regulatory protein

BPSL2972

IclR family regulatory protein

Decreased

NS

IclR/Small-molecule binding

HTH_IclR-DNA binding

BPSL3291 fliA

flagellar biosynthesis sigma factor

Increased

Increased

Not known

Sigma70 -DNA binding

BPSS0070

IS30 transposase

NS

Decreased

Not known

HTH_38-DNA binding

LuxR transcriptional regulator

Increased

Increased

Autoind_bind- Small-molecule
binding

GerE-DNA binding

BPSS0755

LysR family regulatory protein

NS

Increased

LysR_substrate- Small-molecule
binding

HTH_1-DNA binding

BPSS0797

IclR family regulatory protein

NS

Increased

IclR/Small-molecule binding

BPSS0799

Diguanylate phosphodiesterase

Increased

Increased

EAL/Di-guanylate cyclase

BPSS1553 bprP

Transcriptional regulator

Increased

Increased

Trans_reg_C/DNA-binding

BPSS0312 malR

HTH_IclR-DNA binding

Genes were identified as differentially expressed if they showed >2-fold expression change (log2 < −1.0) compared to the wild-type strain with a False Discovery
Rate (FDR) of <0.01
#
Genes showing increased expression of >2-fold with a FDR of >0.01 and <0.05

Lazar Adler et al. BMC Genomics (2016) 17:331

Page 11 of 17

IclR family protein, and dctD, encoding a C4dicarboxylate transport transcriptional response regulator (Table 4).
Perturbation of the BprRS TCSTS affects B. pseudomallei
motility

In the mutants with a single inactivation in either bprS
or bprR, 21 genes involved in flagella biosynthesis were
increased in expression, located in four different locations on chromosome 1 (Table 2). In addition, two genes
encoding
methyl-accepting
chemotaxis
proteins
(bpsl1829 and tar) showed increased expression, and
there was decreased expression of the type-1 fimbrial
gene, bpsl1801 (Table 3) predicted to be involved in attachment to surfaces. Accordingly, we analysed the bprS
mutants (bprS::Tn5 and the bprS directed mutant), the
bprR directed mutant, the parent strain K96243, as well
as the bprRS double mutant, for their ability to migrate
or swarm in a coordinated manner on solid medium.
The parent strain K96243 and the bprRS double mutant
both demonstrated a capacity for rapid swarming, with
the leading edge of the swarming population migrating
to the edge of the agar plate (diameter 80 mm) after
18 h at 37 °C (Fig. 4). However, all strains with either
bprS or bprR inactivated demonstrated a significantly reduced ability to swarm in a coordinated manner (Fig. 4).
To confirm that the reduced swarming motility was due
to perturbation of the BprRS system, we complemented
the bprS directed mutant with the complete bprRS operon in trans. Interestingly, we were unable to clone either bprS or bprR into the multicopy plasmid pBHR1
alone. Swarming motility was fully restored in the
bprS(bprRS) complemented strain, whereas the bprS mutant harbouring empty vector (pBHR1) alone retained
the reduced motility phenotype (Fig. 4). These data show
that inactivation of a single component in the BprRS
TCSTS can reduce the swarming ability of B. pseudomallei.

Discussion
We have identified a putative TCSTS in B. pseudomallei
strain K96243 that is encoded by bprS (bpss0687) encoding the SK, and bprR (bpss0688) encoding the RR. Inactivation of the entire BprRS system did not result in
changes to virulence or motility, and RNA expression
analysis of the bprRS double mutant identified very few
genes that were differentially expressed compared to the
expression in the parent strain K96243. Genes identified
as differentially expressed in the bprRS double mutant
included one (bpss0686) adjacent to the bprS gene, encoding a predicted 5, 10-methylene tetrahydromethanopterin reductase that is required for one carbon
metabolism [23]. Five genes that encoded phage-related
proteins were also identified. Thus, our analysis suggests
that the BprRS TCSTS regulon is small but it is possible

Fig. 4 The B. pseudomallei bprS and bprR mutants display reduced
motility. Swarming motility was measured on agar plates grown at
37 °C for 18 h. Panel a, selected images of motility plates and Panel
b, quantification of the motility data. Strains are B. pseudomallei wildtype (WT), directed bprS mutant (bprS), bprS transposon mutant
(bprS::Tn5), bprR mutant (bprR), bprRS double mutant (bprRS),
complemented bprS mutant (bprS(bprRS)), bprS mutant containing
empty vector (bprS(pBHR1)) and a non-motile fliC mutant control
(panel b only). Data are mean ± SEM. * = P < 0.01

that under different growth conditions, such as during
growth in a host or the environment, other genes may
be identified that belong to the BprRS regulon.
In contrast, inactivation of a single component (bprS
or bprR) of the BprRS TCSTS resulted in the differential
expression of a large number of genes. More than 70
genes were differentially expressed in both the bprS and
bprR mutant and included those involved in flagella biosynthesis, malleilactone biosynthesis, antibiotic resistance, chemotaxis and regulation. In addition, phenotypic
assays showed that the bprS and bprR mutants displayed
reduced growth in mice and reduced swarming motility.
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Together, these results clearly demonstrate that perturbation of the BprRS system, but not inactivation of the
whole system, attenuates B. pseudomallei. We hypothesize
that the changes observed as a result of perturbation of
the BprRS TCSTS arise through cross-regulation with one
or more of the 60 TCSTS encoded on the B. pseudomallei
genome [15]. A number of interactions between TCSTS
have been identified in Escherichia coli; in vitro phosphorylation assays showed that phosphorylation of RRs by
non-cognate SKs was observed for at least 21 pairs [34].
While most E. coli cross-talk interactions are weak [34],
strong cross-talk has been observed between a number of
systems, including CreC and PhoB and the PmrA/B and
QseB/C systems of E. coli [35, 36] Interactions between
PhoB, PmrA/B and QseB/C happen at multiple levels including phosphorylation, dephosphorylation and DNA
binding. The E. coli QseC SK normally acts to dephosphorylate (and deactivate) its cognate RR QseB, but QseB
can be phosphorylated by PmrB at relatively high levels
[36] and the binding of both RRs at the qseBC promoter is
likely to be required for normal gene expression. In the
absence of QseC the phosphorylating activity of PmrB on
QseB is uncontrolled, leading to increased expression of
the QseBC TCSTS and decreased expression of a range of
virulence genes including those involved in pilin and flagellin synthesis. Importantly, while an E. coli qseC mutant
was non-motile and attenuated for virulence, the single
qseB and the double qseBC mutants showed wild-type
virulence and motility [37]. Cross-regulation has been implicated in at least three E. coli TCSTS that affect flagella
synthesis and motility, including predicted interactions between ArcAB and another unidentified TCSTS [38].
Therefore, we propose that in the absence of both BprR
and BprS (i.e. the bprRS double mutant) only the expression of genes within the BprRS regulon is affected. However, in the absence of BprS, BprR is phosphorylated by
one or more, non-cognate sensor kinases and interacts
with genes outside the BprRS regulon. Conversely, we predict that in the absence of BprR, BprS phosphorylates one
or more, non-cognate response regulators. Moreover,
given that a large subset of genes was differentially
expressed in both the bprR and bprS mutants, we propose
that the majority of cross-talk occurs largely with a single,
as yet unidentified, TCSTS cognate pair. This cross-talk
then leads to a cascade of dysregulation, including altered
expression of genes encoding other regulators.
Phenotypic analysis of the mutants revealed that the
bprS and bprR mutants were attenuated for swarming
motility. In both mutants many flagella biosynthesis
genes showed increased expression compared to the
wild-type strain; suggesting that altered motility resulted
from incorrect levels of flagella proteins or dysregulated
timing of expression. Furthermore, genes within the
flagella-associated locus, including fliC encoding the

Page 12 of 17

flagella subunit, were not changed in expression compared to that in the parent strain K96243 supporting the
proposition that the altered motility of the BprS and
BprR mutants may have been affected by an imbalance
in the expression of the flagella biosynthesis and structural components. In E. coli and other bacteria, flagella
synthesis involves the action of numerous and complex
TCSTS interactions, and we predict similar interactions
between regulatory factors is also likely to be essential
for the co-ordinated movement of B. pseudomallei. The
gene bpss0799, encoding a protein with an EAL domain
characteristic of cyclic diguanylate phosphodiesterases,
was increased in expression in both the bprS and bprR
mutants. Cyclic diguanylate phosphodiesterases negatively control levels of bis-(3′-5′)-cyclic dimeric guanosine monophosphate (c-di-GMP) and, together with the
positive regulator diguanylate cyclase, initiate the c-diGMP signalling system in bacteria. The global second
messenger c-di-GMP then binds to specific effector molecules that target, and subsequently affect the expression
of a wide range of genes involved in cellular functions
including motility, biofilm formation and the production
of fimbriae [33]. A previous study identified another B.
pseudomallei gene (cdpA or bpsl1263) as encoding the
cyclic diguanylate phosphodiesterase involved in flagella
function and motility [39]. However, our own bioinformatic analysis (data not shown) indicates that bpsl1263
encodes a protein with both an EAL and a GGDEF domain, the latter domain being characteristic of diguanylate cyclases. Other regulatory genes with increased
expression in the bprS and bprR mutants included two
genes encoding predicted MCPs, bpsl1829 and tar.
MCPs are the trans-membrane sensor proteins of the
chemotaxis pathway that controls bacterial movement in
response to available nutrients or other environmental
stimuli [40]. In E. coli, MCPs directly transfer phosphate
to the TCSTS SK CheA that then transfers the phosphate to one of two RRs, CheY or CheB. Phosphorylated
CheY interacts directly with the flagella motor and
causes a directional change, whereas phosphorylated
CheB acts a methylesterase on the signalling MCP and
modulates the amount of signal [41]. The MCP Tar sensors induce bacterial cells to move towards aspartate/
maltose and away from nickel/cobalt [42]. Bioinformatic
analysis did not provide any information on the type of
sensor the bpsl1829 gene encodes, but we predict that
dysregulation of the expression of either MCP is likely
to have an effect on motility. Although no studies have
been conducted on chemotaxis mutants in any Burkholderia species, a study in a close relative, Ralstonia solanacearum, showed that a cheA mutant displayed
significantly reduced virulence [43].
The genes bprP and bprQ, involved in the BsaN virulence regulon, both displayed increased expression when
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the BprRS TCSTS was perturbed. A recent transcriptomic study of a B. pseudomallei bsaN deletion mutant
elucidated components of the BsaN virulence-associated
regulatory system [32]. It is proposed that BprP directly
activates the Ara-C like regulatory protein BsaN that, together with the T3SS3 chaperone BicA, act as a dualfunction regulatory complex that controls the expression
of the T6SS-1 (via activation of the VirAG TCSTS) and
the T3SS3 effectors (bopA, bopC and bopE). In addition,
in the bsaN mutant the TTSS3 genes showed increased
expression, while the genes involved in malleilactone
(bpss0303-0311) and flagella biosynthesis (bpsl0281,
bpsl3319, bpsl3320, bpsl3321) showed decreased expression [32]. In our study, we observed an increase in expression of bprP and bprQ, but not the gene encoding
the chaperone BicA. We also observed an increase in expression of malleilactone-associated and flagellaassociated genes, but no significant change in expression
of genes associated with the T3SS3 and T6SS-1. Nevertheless, it is possible that an imbalance in the expression
of the proteins that initiate the transcription of bsaN
(BprP/BicA) may have an effect on the expression of
some genes within the BsaN regulon.
Perturbation of the BprRS TCSTS reduced the in vivo
fitness of B. pseudomallei and this may, or may not have
been directly associated with the loss of motility. An initial report demonstrated that a non-flagellated fliC mutant constructed in B. pseudomallei strain 1026b was
not attenuated for virulence in BALB/c mice, diabetic
rats or Syrian hamsters [44, 45]. In contrast, a fliC mutant of a more virulent strain of B. pseudomallei (KHW)
was attenuated for virulence in BALB/c mice [46].

Conclusions
Phenotypic and transcriptomic analyses of a newly identified TCSTS BprRS, revealed that perturbation of the
system via inactivation of the SK BprS or the RR BprR
led to a reduction in virulence and reduced motility, as
well as a wide range of gene expression changes. Our results support the concept that B. pseudomallei TCSTS
regulatory networks can interact and show that selective
perturbation of these systems can lead to attenuation of
B. pseudomallei. Together our results highlight the need
for further systematic studies of B. pseudomallei TCSTS
regulation and show that targeting a single TCSTS component can attenuate virulence.
Methods
Bacterial strains, plasmids and culture conditions

The B. pseudomallei strain K96243 is a human clinical
isolate obtained from Thailand [15]. B. pseudomallei directed mutants were generated by double cross-over insertional mutagenesis using recombinant derivatives of
the λ pir-dependent plasmid pDM4 [47]. All pDM4
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derivatives were maintained in E. coli SM10 λ pir (thi
thr leu tonA lacY supE recA RP4-2-Tc::Mu::Km pir), or
E. coli S17-1 λ pir (thi pro hsdR hsdM1 recA RP4-2Tc::Mu-Km::Tn7 pir). For some clonings, pBlueScriptSK(Stratagene) was used as an intermediate vector prior to
transfer of the insert into pDM4. The pBlueScript derivatives were grown in E. coli DH5α cells (F− endA1
hsdR17 (r−k m−k ) glnV44 thi-1 λ− recA1 gyrA96 relA1
Δ(argF- lacZYA)U196 ϕ80dlacZ ΔM15). The tetracycline resistance gene tetA(C) was used for selection of B.
pseudomallei mutants and was isolated from either
pUTminiTn5Tc (Biomedal S. L., Spain) or pWH1266
[48]. For complementation, the BprRS operon was
cloned into the plasmid pBHR1, a derivative of the
mobilizable broad-host-range plasmid pBBR1 [49]. All E.
coli strains were routinely grown on lysogeny broth (LB)
medium with or without selection. B. pseudomallei
K96243 and derivatives were grown using either LB,
yeast-tryptone medium (2YT), minimal medium (M9),
or Ashdown’s medium (containing 64 μg/ml gentamicin). All strains were grown at 37 °C (liquid cultures
with 200 rpm agitation).
Construction and screening of B. pseudomallei signaturetagged mutagenesis library

A B. pseudomallei signature-tagged mutagenesis library
was constructed using a modified miniTn5 transposon
(Biomedal S.L., Spain). Briefly, 42 unique DNA-tags were
amplified from the STM-adapted Tn916 transposons
generated by Harper et al. [50] and cloned into the
unique NotI site of pUTminiTn5Tc. The 42 uniquelytagged transposons were then separately introduced into
B. pseudomallei by conjugation and pools of 42 mutants
collected. Each STM pool was then screened for reduced
in vivo growth in BALB/c mice [51]. An input pool inoculum of approximately 2 × 108 CFU was used to inoculate two 8–10 week old, female BALB/c mice by the
i.n. route. DNA recovered from pooled input colonies
and pooled output colonies (harvested from spleen), was
used to generate digoxygenin-labelled (Roche) DNA
probes representing tags present in each sample. Labelled probes were then used in dot blot hybridizations
to determine the presence/absence of each mutant in input and output pools as described previously [50].
Generation of bprS, bprR and bprRS double cross-over
mutants

The bprS, bprR and bprRS mutants were constructed by
double cross-over insertional mutagenesis using the λ
pir-dependent vector pDM4 [47] which carries a chloramphenicol resistance gene for selection and the
counter-selectable sacB gene. To generate the bprS mutagenesis construct, an internal fragment of bprS was
disrupted by cloning of the miniTn5 tetA(C) gene into
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the bprS BglII site. Insertion of the tetA(C) gene at this
BglII site results in the termination of BprS translation
at the second transmembrane region (Fig. 1). Briefly, the
primers BAP4787 (5′ TTCGTGCTGCAGGATTATC
TCGAACGCCATCC 3′) containing a PstI site, and
BAP4788 (5′ CGAATCTCTAGAGTGGAACGGCTCG
AACAC 3′) containing an XbaI site, were used to amplify a 981 bp PCR product from within the B. pseudomallei K96243 bprS gene. This PCR fragment,
containing an internal BglII site, was digested with PstI
and XbaI and ligated into similarly digested pDM4.
Primers BAP3325 (5′ CGGCTTAGATCTAGGTCGA
GGTGGCC 3′) and BAP4629 (5′ TCCACCAGATCTATTTGCCGACTACCTTGGTG 3′), both containing a
BglII site, were used to amplify the miniTn5 tetA(C)
gene. This PCR product and pDM4 containing the bprS
internal fragment were digested with BglII and ligated to
generate the plasmid pAL603 which was then introduced by transformation into E. coli SM10 λ pir.
For generation of the bprR mutagenesis construct,
pBluescriptSK- was used as an intermediate plasmid
prior to cloning into pDM4. Primers BAP6698 (5′ GA
ACACCCCGGGCGCGAGATCGACATGCCCGGACAC
GCC 3′) containing an XmaI site, and BAP6699 (5′
CGTCGTACTAGTACATGAAGCCGAAGCCCTCGTT
GCCG 3′) containing an SpeI site, were used to amplify
a 1648 bp PCR product from B. pseudomallei K96243
encompassing the entire bprR gene, 687 bp of upstream and 241 bp of downstream DNA. This PCR
product, containing an internal AatII site within bprR
(Fig. 1a) was digested with XmaI and SpeI and ligated
into similarly digested pBluescriptSK-. Primers BAP6700
(5′ AAAACAGACGTCTTGCTAACGCAGT 3′) and
BAP6701 (5′ AAAAATGACGTCAGTGGTGAATCC 3′),
both containing an AatII site, were used to amplify the
tetA(C) gene from pWH1266. This product and the
pBluescriptSK- derivative containing the bprR fragment
were digested with AatII and ligated to generate the
plasmid pBluescriptSK::bprR-tet which was then introduced into E. coli DH5α by transformation. This
insertion of the tetracycline resistance gene at the internal AatII site causes a truncation of bprR within
the initial receiver domain (Fig. 1a). The fragment
containing the disrupted bprR was released from
pBluescriptSK::bprR-tet by digestion with XmaI and
SpeI and ligated into pDM4, generating the plasmid
pAL1067 which was then introduced into E. coli
SM10 λ pir cells.
To generate the bprRS double mutant, up- and downstream regions encompassing the 5′ and 3′ ends of bprR
and bprS respectively were cloned into pBluescriptSK-,
with the tetA(C) gene from miniTn5 gene inserted between the two fragments. Insertion of this construct into
the genome leads to deletion of a 3′ segment of bprR
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(encoding part of the receiver domain and all of the effector domain) as well as deletion of a 5′ segment of
bprS (encoding both transmembrane regions and the
HAMP and HisKA domains) (Fig. 1b). Briefly, primers
BAP6704 (5′ TCGACGCCCGGGTCACCGAGCTGCTGACGATCGGC 3′) containing an XmaI site, and
BAP6705 (5′ CGGCGCACTAGTTATCAGACCGACTACGCGCC 3′), containing a SpeI site, were used to
amplify a 973 bp PCR fragment including the 3′ end of
bprS and down-stream flanking DNA. This product was
digested with appropriate enzymes and ligated into
pBluescriptSK- digested with XmaI and SpeI and introduced into DH5α cells. Primers BAP6685 (5′ AAAACAGAATTCTTGCTAACGCAGT 3′) and BAP6686 (5′
AAAAATGAATTCAGTGGTGAATCC 3′), both containing an EcoRI site, were used to amplify the tetA(C)
gene from pWH1266. This product and pBluescriptSKcontaining the DNA fragment containing bprS and
flanking region were digested with EcoRI, ligated and
introduced into E. coli DH5α. Primers BAP6702 (5′
AGCGGCGGGCCCCCGCATGCACCGAGCCC 3′) containing an ApaI site, and BAP6703 (5′ GAGGCCATCGATTTGATCGTAGACGTCCG 3′) containing a ClaI
site, were used to amplify a 1021 bp PCR product
encompassing the 5′ end of bprR and up-stream flanking DNA. This product was digested with ApaI and
ClaI and ligated into the similarly digested pBluescriptSK- containing bprS plus flanking region and the
tetA(C) gene, and then introduced into E. coli DH5α
cells, generating the plasmid pAL1062. This plasmid
was digested with ApaI and SpeI and the fragment containing bprR-tet-bprS was ligated into pDM4. The
resulting plasmid, designated pAL1066, was then introduced into E. coli SM10 λ pir cells.
Each of the recombinant plasmids pAL603,
pAL1067 and pAL1066 was mobilised from E. coli
SM10 λ pir into B. pseudomallei K96243 by conjugation and putative double cross-over mutants were
selected on LB agar containing gentamicin (8 μg/mL)
and tetracycline (25 μg/mL). All mutations were
confirmed by PCR and sequence analysis (data not
shown).
Complementation of the bprS mutant

The bprS mutant was complemented by cloning an intact copy of the bprRS operon into the multicopy plasmid pBHR1. Primers BAP7136 (5′ CGGCGCTTTAA
AGGCTCGATACTGACTGCTGCCGGC 3′) containing
a DraI site, and BAP7137 (5′ CGCGCGCCATGGAT
CGTCTGACGGCCGAAACC 3′) containing an NcoI
site, were used to amplify a 2483 bp PCR product from
B. pseudomallei K96243. This fragment encoded bprS
and bprR as well as 353 bp of the upstream region predicted to contain the bprRS promoter. The PCR
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product was digested with DraI and NcoI and ligated
into similarly digested pBHR1, disrupting the cat gene
and generating the plasmid pBHR1::bprRS. This plasmid was then introduced into E. coli S-17 λ pir and
kanamycin resistant, chloramphenicol sensitive clones
selected. The pBHR1::bprRS plasmid and empty pBHR1
(negative control) were separately mobilised from E.
coli S-17 into the bprS mutant by conjugation. Recombinants containing the pBHR1::bprRS plasmid were selected on LB agar containing kanamycin (1000 μg/mL)
and tetracycline (25 μg/mL) while those containing the
empty pBHR1 plasmid were selected on LB agar
containing kanamycin (1000 μg/mL), tetracycline
(25 μg/mL) and chloramphenicol (40 μg/mL). Strains
containing the correct plasmids were identified by PCR
and nucleotide sequence analysis (data not shown).
Neither bprR nor bprS alone could be cloned into the
pBHR1 plasmid despite numerous attempts.
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when moribund, in accordance with animal ethics
requirements. The ID50 for the parent strain K96243
and mutant strain was determined using the calculation
described by Reed and Muench [52] based on cumulative moribund infections. For direct virulence assays, differences in survival were calculated using Fisher’s exact
test and differences in time to death determined using
the log-rank Mantel-Cox test. Spleens from three mice
in each group were harvested, homogenised in PBS and
plated onto LB agar. The stability of the mutants was
assessed by patching the recovered colonies onto agar
plates with or without tetracycline (25 μg/ml). All of the
mutations were stable over the time course of the
experiment. The virulence of the complementation
strain bprS(bprRS) could not be assessed as the complementation plasmid was highly unstable in the absence of
antibiotic selection (>90 % plasmid loss over 16 h).
RNA purification

Competitive in vivo growth assays

Overnight cultures of B. pseudomallei wild-type parent
strain K96243 and the bprS mutant were grown in LB to
an optical density at 600 nm (OD600) of 0.2. Equal volumes of K96243 and bprS mutant culture were combined
and 20 μl (containing approximately 4 × 105 CFU) of an
appropriate dilution was used to infect three 6–8 weekold female BALB/c mice by the i.n. route. After 24 h, mice
were euthanized in accordance with animal ethics requirements. Spleens were harvested, homogenised in phosphatebuffered saline pH = 7.2 (PBS) and plated onto LB agar.
After growth at 37 °C for 24 h, 100 colonies from these in
vivo growth plates and 100 colonies representing the input
culture were patched onto LB agar with or without tetracycline (25 μg/ml) to determine the proportion of bprS mutant to K96243 wild-type bacteria. The competitive index
was calculated as the proportion of mutant to wild-type
bacteria recovered from the mouse spleens divided by the
proportion of mutant to wild-type bacteria present in the
input inoculum.
Virulence assays

Overnight cultures of the parent strain K96243 and the
bprS, bprR and bprRS mutants were subcultured in fresh
medium with appropriate antibiotics and grown to midlog phase to an OD600 of 0.8 (equivalent to ~5.0 ×
108 CFU/ml). For the ID50 assays, groups of five 8–10
week-old BALB/c mice were either inoculated i.n (1.0 ×
106 CFU in 20 μl volume) or injected i.p (1.0 × 103 CFU
in 200 μl volume) with LB containing mid-exponential
phase bacteria. For the direct virulence assays, groups of
nine 6–8 week-old, female BALB/c mice were infected
i.n. with 20 μl doses containing approximately 5.0 ×
104 CFU. Mice were monitored for 10 days for signs of
disease and euthanized at the end of the experiment or

B. pseudomallei parent strain K96243 and the directed
bprS, bprR and bprRS mutants were grown overnight at
37 °C in LB with appropriate antibiotics (K96243 in gentamicin 64 μg/ml; mutants in gentamicin 64 μg/ml and
tetracycline 25 μg/ml). Strains were subcultured 1/50
into fresh antibiotic-free medium and grown at 37 °C
with shaking (200 rpm) to an OD600 of 0.5. The cells
were harvested by centrifugation, and RNA purified
using Trizol reagent (Gibco/BRL) as specified by the
manufacturer. RNA was DNase treated using the
TURBO DNA-free kit (Ambion), followed by processing
with a QIAGEN RNeasy kit clean-up with on-column
DNase digestion as per the manufacturer’s instructions.
High-throughput RNA sequencing

Double-stranded cDNA synthesis and high-throughput
RNA-seq were performed as described previously [53].
For each strain three biological replicates were sequenced.
Trimmed sequence reads were aligned to the B. pseudomallei K96423 genome sequence using SHRiMP [54] and
normalised read counts were compared using voom and
limma as described previously [53]. For each replicate
sample, between 6.4 million and 14.0 million sequence
reads were mapped uniquely to the K96423 genome sequence. The RNA-seq data is available at the NCBI Gene
Expression Omnibus; accession number GSE77970. Differentially expressed genes were identified as those with a
greater than 2-fold change in expression (1.0 log2) across
all replicates at a false discovery rate (FDR) of <0.01.
Swarming motility assays

Swarming agar plates were prepared fresh on the day of
the assay using the modified protocol of Tunpiboonsak
et al. [55]. Briefly, plates were prepared using 0.5 % w/v
agar-agar (Merck), 8 g/L nutrient broth No.2 (Oxoid)
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and 5 g/L D(+)- glucose (dextrose) (May and Baker) and
dried carefully to give constant moisture content. Overnight cultures of B. pseudomallei parent strain K96243
and mutant strains were subcultured 1/50 into fresh
medium with appropriate antibiotics (no selection for
parent strain, 25 μg/ml tetracycline for all mutants and
complemented mutants) and grown at 37 °C with shaking (200 rpm) to late exponential phase (OD600 of ~2.5).
A 5 μl volume of each culture was spotted onto the
centre of a swarming agar plate which was then incubated at 37 °C for 18 h in the dark. The diameter of the
swarming population was then measured. Statistical analysis of swarming distance was determined by Student’s
t-test with a P-value of <0.05 considered significant.

Page 16 of 17

Funding
This work was funded by the Australian Research Council (Australia), Australian
Research Council Centre of Excellence in Structural and Functional Microbial
Genomics Grant number CE0562063 and the National Health and Medical
Research Council (Australia), Project Grant numbers 545855 and 1043667.
Author details
1
Department of Microbiology, Monash University, 19 Innovation Walk,
Clayton, Victoria 3800, Australia. 2Infection and Immunity Program, Monash
Biomedicine Discovery Institute, Monash University, Victoria, Australia.
3
Victorian Bioinformatics Platform, Monash University, Victoria, Australia.
4
Department of Biochemistry and Molecular Biology, Monash University,
Victoria, Australia. 5Department of Microbiology and Immunology, James
Cook University, Townsville, Queensland, Australia. 6Core Biotechnology
Services, University of Leicester, Leicester LE1 9HN, UK. 7Department of
Molecular Microbiology, Washington University School of Medicine, St. Louis,
MO, USA. 8Faculty of Dentistry, National University of Singapore, Singapore,
Singapore.
Received: 26 November 2015 Accepted: 26 April 2016

Ethics approval and consent to participate

All animal experiments were carried out in accordance
with the provisions of the “Prevention of Cruelty to Animal Act, 1986”, the “Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes 7th edition, 2004” and the Monash University Animal Welfare
Committee Guidelines and Policies. The protocol was
approved by the Monash Animal Research Platform
(MARP)-2 Animal Ethics Committee (AEC) of Monash
University (AEC number MARP/2011/067).
Consent for publication

Not applicable.
Availability of data and materials

The RNA-seq data is available at the NCBI Gene
Expression Omnibus; accession number GSE77970.
Abbreviations
2YT: yeast-tryptone medium; AEC: Animal Ethics Committee; FDR: false
discovery rate; HAMP: Histidine kinases, Adenyl cyclases, Methyl-accepting
proteins and Phosphatases; HATPase_c: Histidine kinase-like ATPase, Cterminal domain; HisKA: histidine kinase A domain; i.n.: intranasal;
i.p.: intraperitoneal; LB: lysogeny broth; MARP: Monash Animal Research
Platform; MCPs: methyl-accepting chemotaxis proteins; OD600: optical density
at 600 nm; PBS: phosphate-buffered saline pH = 7.2; RNA-seq: RNA
sequencing; RND: resistance-nodulation-division; RR: response regulator;
SK: sensor kinase; T6SS-1: type VI secretion system cluster 1; T6SS-2: type 6
secretion system cluster 2; TCSTS: two-component signal transduction
system; TTSS3: type III secretion system locus 3.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NLA, EA, DDL, SW, AD, BA, PT and PA performed the experiments. PH, DDL, EA,
NLA, MH, JB performed statistical and bioinformatic analysis on the RNA-seq
transcriptomic data. EA, NLA, BA, RD, MH and JB wrote and edited the manuscript.
NLA, EA, BG, RD, MP, BA, MH and JB supervised the study. All authors read and
approved the final manuscript
Acknowledgements
We thank Carla Osinski for excellent technical assistance and Alicia Shu-Chin
Lai for her considerable help with animal experiments.

References
1. Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of
melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS
Negl Trop Dis. 2010;4, e900.
2. Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N,
Wongsuvan G, Chaisuksant S, Chetchotisakd P, et al. Increasing
incidence of human melioidosis in Northeast Thailand. Am J Trop Med
Hyg. 2010;82:1113–7.
3. Stone R. Infectious disease. Racing to defuse a bacterial time bomb. Science.
2007;317:1022–4.
4. Douglas MW, Lum G, Roy J, Fisher DA, Anstey NM, Currie BJ.
Epidemiology of community-acquired and nosocomial bloodstream
infections in tropical Australia: a 12-month prospective study. Trop Med
Int Health. 2004;9:795–804.
5. Chaowagul W, White NJ, Dance DA, Wattanagoon Y, Naigowit P, Davis TM,
Looareesuwan S, Pitakwatchara N. Melioidosis: a major cause of communityacquired septicemia in northeastern Thailand. J Infect Dis. 1989;159:890–9.
6. Livermore DM, Chau PY, Wong AI, Leung YK. beta-Lactamase of
Pseudomonas pseudomallei and its contribution to antibiotic resistance. J
Antimicrob Chemother. 1987;20:313–21.
7. Moore RA, DeShazer D, Reckseidler S, Weissman A, Woods DE. Efflux-mediated
aminoglycoside and macrolide resistance in Burkholderia pseudomallei.
Antimicrob Agents Chemother. 1999;43:465–70.
8. Schweizer HP. Efflux as a mechanism of resistance to antimicrobials in
Pseudomonas aeruginosa and related bacteria: unanswered questions. Genet
Mol Res. 2003;2:48–62.
9. Hoch JA. Two-component and phosphorelay signal transduction. Curr Opin
Microbiol. 2000;3:165–70.
10. Stock AM, Robinson VL, Goudreau PN. Two-component signal transduction.
Annu Rev Biochem. 2000;69:183–215.
11. Krell T, Lacal J, Busch A, Silva-Jimenez H, Guazzaroni ME, Ramos JL. Bacterial
sensor kinases: diversity in the recognition of environmental signals. Annu
Rev Microbiol. 2010;64:539–59.
12. Gao R, Stock AM. Biological insights from structures of two-component
proteins. Annu Rev Microbiol. 2009;63:133–54.
13. Gotoh Y, Eguchi Y, Watanabe T, Okamoto S, Doi A, Utsumi R. Two-component
signal transduction as potential drug targets in pathogenic bacteria. Curr Opin
Microbiol. 2010;13:232–9.
14. Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ. The biology and future
prospects of antivirulence therapies. Nat Rev Microbiol. 2008;6:17–27.
15. Holden MT, Titball RW, Peacock SJ, Cerdeno-Tarraga AM, Atkins T, Crossman LC,
Pitt T, Churcher C, Mungall K, Bentley SD, et al. Genomic plasticity of the
causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci U S
A. 2004;101:14240–5.
16. Wiersinga WJ, de Vos AF, de Beer R, Wieland CW, Roelofs JJ, Woods DE,
van der Poll T. Inflammation patterns induced by different Burkholderia
species in mice. Cell Microbiol. 2008;10:81–7.
17. Jones AL, DeShazer D, Woods DE. Identification and characterization of a
two-component regulatory system involved in invasion of eukaryotic cells

Lazar Adler et al. BMC Genomics (2016) 17:331

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

29.
30.

31.

32.

33.
34.

35.

36.

37.

and heavy-metal resistance in Burkholderia pseudomallei. Infect Immun.
1997;65:4972–7.
Mahfouz ME, Grayson TH, Dance DA, Gilpin ML. Characterization of the mrgRS
locus of the opportunistic pathogen Burkholderia pseudomallei: temperature
regulates the expression of a two-component signal transduction system. BMC
Microbiol. 2006;6:70.
Chen Y, Wong J, Sun GW, Liu Y, Tan GY, Gan YH. Regulation of type VI
secretion system during Burkholderia pseudomallei infection. Infect Immun.
2011;79:3064–73.
Tuanyok A, Tom M, Dunbar J, Woods DE. Genome-wide expression analysis
of Burkholderia pseudomallei infection in a hamster model of acute
melioidosis. Infect Immun. 2006;74:5465–76.
Cuccui J, Easton A, Chu KK, Bancroft GJ, Oyston PC, Titball RW, Wren BW.
Development of signature-tagged mutagenesis in Burkholderia pseudomallei
to identify genes important in survival and pathogenesis. Infect Immun.
2007;75:1186–95.
Atkins T, Prior R, Mack K, Russell P, Nelson M, Prior J, Ellis J, Oyston PC,
Dougan G, Titball RW. Characterisation of an acapsular mutant of
Burkholderia pseudomallei identified by signature tagged mutagenesis. J
Med Microbiol. 2002;51:539–47.
Chistoserdova L, Chen SW, Lapidus A, Lidstrom ME. Methylotrophy in
Methylobacterium extorquens AM1 from a genomic point of view. J Bacteriol.
2003;185:2980–7.
Chan YY, Tan TM, Ong YM, Chua KL. BpeAB-OprB, a multidrug efflux
pump in Burkholderia pseudomallei. Antimicrob Agents Chemother.
2004;48:1128–35.
Tribuddharat C, Moore RA, Baker P, Woods DE. Burkholderia pseudomallei
class a beta-lactamase mutations that confer selective resistance against
ceftazidime or clavulanic acid inhibition. Antimicrob Agents Chemother.
2003;47:2082–7.
Rholl DA, Papp-Wallace KM, Tomaras AP, Vasil ML, Bonomo RA, Schweizer
HP. Molecular Investigations of PenA-mediated beta-lactam Resistance in
Burkholderia pseudomallei. Front Microbiol. 2011;2:139.
Harland DN, Dassa E, Titball RW, Brown KA, Atkins HS. ATP-binding cassette
systems in Burkholderia pseudomallei and Burkholderia mallei. BMC
Genomics. 2007;8:83.
Burtnick MN, Brett PJ, Harding SV, Ngugi SA, Ribot WJ, Chantratita N,
Scorpio A, Milne TS, Dean RE, Fritz DL, et al. The cluster 1 type VI secretion
system is a major virulence determinant in Burkholderia pseudomallei. Infect
Immun. 2011;79:1512–25.
Seyedsayamdost MR. High-throughput platform for the discovery of elicitors
of silent bacterial gene clusters. Proc Natl Acad Sci U S A. 2014;111:7266–71.
Truong TT, Seyedsayamdost M, Greenberg EP, Chandler JR. A Burkholderia
thailandensis acyl-homoserine lactone-independent orphan luxr homolog
that activates production of the cytotoxin malleilactone. J Bacteriol. 2015;
197:3456–62.
Sun GW, Chen YH, Liu YC, Tan GYG, Ong C, Tan P, Gan YH. Identification of
a regulatory cascade controlling Type III Secretion System 3 gene
expression in Burkholderia pseudomallei. Mol Microbiol. 2010;76:677–89.
Chen YH, Schroder I, French CT, Jaroszewicz A, Yee XJ, Teh BE, Toesca IJ,
Miller JF, Gan YH. Characterization and analysis of the Burkholderia
pseudomallei BsaN virulence regulon. BMC Microbiol. 2014;14:206.
Hengge R. Principles of c-di-GMP signalling in bacteria. Nat Rev Microbiol.
2009;7:263–73.
Yamamoto K, Hirao K, Oshima T, Aiba H, Utsumi R, Ishihama A. Functional
characterization in vitro of all two-component signal transduction systems
from Escherichia coli. J Biol Chem. 2005;280:1448–56.
Amemura M, Makino K, Shinagawa H, Nakata A. Cross talk to the phosphate
regulon of Escherichia coli by PhoM protein: PhoM is a histidine protein
kinase and catalyzes phosphorylation of PhoB and PhoM-open reading
frame 2. J Bacteriol. 1990;172:6300–7.
Guckes KR, Kostakioti M, Breland EJ, Gu AP, Shaffer CL, Martinez 3rd CR,
Hultgren SJ, Hadjifrangiskou M. Strong cross-system interactions drive the
activation of the QseB response regulator in the absence of its cognate
sensor. Proc Natl Acad Sci U S A. 2013;110:16592–7.
Kostakioti M, Hadjifrangiskou M, Pinkner JS, Hultgren SJ. QseC-mediated
dephosphorylation of QseB is required for expression of genes
associated with virulence in uropathogenic Escherichia coli. Mol
Microbiol. 2009;73:1020–31.

Page 17 of 17

38. Oshima T, Aiba H, Masuda Y, Kanaya S, Sugiura M, Wanner BL, Mori H,
Mizuno T. Transcriptome analysis of all two-component regulatory system
mutants of Escherichia coli K-12. Mol Microbiol. 2002;46:281–91.
39. Lee HS, Gu F, Ching SM, Lam Y, Chua KL. CdpA is a Burkholderia pseudomallei
cyclic di-GMP phosphodiesterase involved in autoaggregation, flagellum
synthesis, motility, biofilm formation, cell invasion, and cytotoxicity. Infect
Immun. 2010;78:1832–40.
40. Sourjik V, Wingreen NS. Responding to chemical gradients: bacterial
chemotaxis. Curr Opin Cell Biol. 2012;24:262–8.
41. Roberts MA, Papachristodoulou A, Armitage JP. Adaptation and control
circuits in bacterial chemotaxis. Biochem Soc Trans. 2010;38:1265–9.
42. Reader RW, Tso WW, Springer MS, Goy MF, Adler J. Pleiotropic aspartate
taxis and serine taxis mutants of Escherichia coli. J Gen Microbiol.
1979;111:363–74.
43. Yao J, Allen C. Chemotaxis is required for virulence and competitive
fitness of the bacterial wilt pathogen Ralstonia solanacearum. J
Bacteriol. 2006;188:3697–708.
44. DeShazer D, Brett PJ, Carlyon R, Woods DE. Mutagenesis of Burkholderia
pseudomallei with Tn5-OT182: isolation of motility mutants and
molecular characterization of the flagellin structural gene. J Bacteriol.
1997;179:2116–25.
45. Wikraiphat C, Charoensap J, Utaisincharoen P, Wongratanacheewin S,
Taweechaisupapong S, Woods DE, Bolscher JG, Sirisinha S. Comparative in
vivo and in vitro analyses of putative virulence factors of Burkholderia
pseudomallei using lipopolysaccharide, capsule and flagellin mutants. FEMS
Immunol Med Microbiol. 2009;56:253–9.
46. Chua KL, Chan YY, Gan YH. Flagella are virulence determinants of
Burkholderia pseudomallei. Infect Immun. 2003;71:1622–9.
47. Milton DL, O’Toole R, Horstedt P, Wolf-Watz H. Flagellin A is essential for the
virulence of Vibrio anguillarum. J Bacteriol. 1996;178:1310–9.
48. Hunger M, Schmucker R, Kishan V, Hillen W. Analysis and nucleotide
sequence of an origin of DNA replication in Acinetobacter calcoaceticus and
its use for Escherichia coli shuttle plasmids. Gene. 1990;87:45–51.
49. Szpirer CY, Faelen M, Couturier M. Mobilization function of the pBHR1
plasmid, a derivative of the broad-host-range plasmid pBBR1. J Bacteriol.
2001;183:2101–10.
50. Harper M, Boyce JD, Wilkie IW, Adler B. Signature-tagged mutagenesis of
Pasteurella multocida identifies mutants displaying differential virulence
characteristics in mice and chickens. Infect Immun. 2003;71:5440–6.
51. Leakey AK, Ulett GC, Hirst RG. BALB/c and C57Bl/6 mice infected with
virulent Burkholderia pseudomallei provide contrasting animal models for
the acute and chronic forms of human melioidosis. Microb Pathog.
1998;24:269–75.
52. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints.
Amer J Hyg. 1938;27:493–7.
53. Henry R, Crane B, Powell D, Deveson Lucas D, Li Z, Aranda J, Harrison P,
Nation RL, Adler B, Harper M, et al. The transcriptomic response of
Acinetobacter baumannii to colistin and doripenem alone and in
combination in an in vitro pharmacokinetics/pharmacodynamics model. J
Antimicrob Chemother. 2015;70:1303–13.
54. Rumble SM, Lacroute P, Dalca AV, Fiume M, Sidow A, Brudno M.
SHRiMP: accurate mapping of short color-space reads. PLoS Comput
Biol. 2009;5, e1000386.
55. Tunpiboonsak S, Mongkolrob R, Kitudomsub K, Thanwatanaying P,
Kiettipirodom W, Tungboontina Y, et al. Role of a Burkholderia pseudomallei
polyphosphate kinase in an oxidative stress response, motilities, and biofilm
formation. J Microbiol. 2010;48:63–70.

